OptiNose (NASDAQ:OPTN) – Equities researchers at Jefferies Group lifted their Q2 2018 earnings per share estimates for shares of OptiNose in a note issued to investors on Tuesday, May 15th. Jefferies Group analyst D. Steinberg now anticipates that the company will earn ($0.73) per share for the quarter, up from their prior forecast of ($0.74). Jefferies Group also issued estimates for OptiNose’s Q3 2018 earnings at ($0.71) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($3.01) EPS, FY2019 earnings at ($2.72) EPS, FY2021 earnings at $0.85 EPS and FY2022 earnings at $2.72 EPS.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. OptiNose has an average rating of “Buy” and a consensus target price of $29.25.
OptiNose (NASDAQ:OPTN) last issued its earnings results on Monday, May 14th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.07). The firm had revenue of $0.87 million for the quarter.
Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new stake in shares of OptiNose during the 4th quarter valued at approximately $162,000. TIAA CREF Investment Management LLC bought a new stake in shares of OptiNose during the 4th quarter valued at approximately $173,000. Teachers Advisors LLC bought a new stake in shares of OptiNose during the 4th quarter valued at approximately $184,000. Millennium Management LLC bought a new stake in shares of OptiNose during the 4th quarter valued at approximately $190,000. Finally, Deutsche Bank AG bought a new stake in shares of OptiNose during the 4th quarter valued at approximately $247,000. 29.86% of the stock is currently owned by institutional investors.
In related news, CEO Peter K. Miller purchased 5,054 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were bought at an average cost of $18.58 per share, with a total value of $93,903.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 67.80% of the company’s stock.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.